Correlation of expressions of ER/PR/HER-2 receptor status with clinicopathological parameters in Mauritian breast cancer patients.
Version: 1,
Uploaded by: Administrator,
Date Uploaded:
25 November 2022
Warning
You are about to be redirected to a website not operated by the Mauritius Research and Innovation Council. Kindly note that we are not responsible for the availability or content of the linked site. Are you sure you want to leave this page?
Background: Breast cancer is by far the commonest site of cancer registered in Mauritius with an ASR of 56.0/105 in females. This study intends to correlate the expressions of HER-2, estrogen receptor (ER) and progesterone receptor (PR) with clinicopathological parameters in breast carcinoma. It is in fact the ever first study of its kind to be carried out in the Mauritian context. Methods: A prospective study was conducted during a period of two years (2013-2014) at the Central Health Laboratory, Victoria Hospital; whereby 78 paraffin blocks of consecutive breast cancer cases diagnosed were subjected to ER/ PR testing by immunohistochemistry (IHC). As regards to HER-2 testing, they were sent to Lancet laboratories, South Africa for IHC. Chi-Square test was used to evaluate IHC results with prognostic parameters for breast cancer. Results: In the present study, 77 were females and 1 was male; the mean age of patients was 52.7 years ranging from 26 to 80 years, 33 patients (42.3%) were below 50 years of age. 52 cases had defined menopausal status, 67.3% were post-menopausal and 32.7% were pre-menopausal. Infiltrating ductal carcinoma (NOS) was the commonest 48/78 (61.5%) and the other variants 30/78 (38.5%). The overall immunoexpression of ER/PR/HER-2 were 73.6%, 61.8%, 35.9% respectively; HER-2 was overexpressed (3+) in 23.3% of cases and triple negative cases accounted for 17.9%. In terms of laterality, we found that right breast was slightly more involved (53.9%) than left breast (46.2%). ER/PR positivity was associated with Lymph node involvement with marginal significance (p = 0.074). No significant association was found between ER/PR/HER2 as well as with age, tumor size and grade. Conclusions: There are high rates of positive expressions of ER/PR/HER-2/neu among the Mauritian population with breast carcinoma. This year the Central Health Laboratory is planning to set up a comprehensive IHC service with on-site testing for HER-2; hence further studies are to be anticipated on the topic.
Keywords
Breast cancer,Mauritius,estrogen and progesterone receptors,immunohistochemistry
